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Study Objectives
Miranda Kirby, PhD,1,2 Damien Pike, BSc,3,4 David G. McCormack, MD, FRCPC,5 Don D. Sin, MD, FRCPC,2,6 
Stephen Lam, MD, FRCPC,7 Harvey O. Coxson, PhD,1,2* and Grace Parraga, PhD3,4*
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Although the human and societal burden and cost of COPD is staggering, there are few clinical tools that provide 
earlier diagnoses or a means to regionally monitor disease in a way that might lead to improved therapies and 
outcomes.  In acknowledgement of the current gaps in COPD therapy, the objective of the Thoracic Imaging 
Network of Canada (TINCan) is to improve COPD patient phenotyping through imaging, to provide methods and 
imaging-based intermediate endpoints for the development of new treatments, and to evaluate disease progression 
and patient-based outcomes in COPD patients and those at risk of COPD.  Here we summarize and outline the 
TINCan study protocol and describe our objectives.  TINCan is a prospective study that aims to identify and 
quantify novel COPD phenotypes from thoracic computed tomography (CT) and thoracic hyperpolarized noble 
gas magnetic resonance imaging (MRI) in 200 ex-smokers, 50 years of age or greater, including asymptomatic 
ex-smokers with normal pulmonary function and Global initiative for chronic Obstructive Lung Disease (GOLD) 
Unclassified (U) , and GOLD stages I-IV patients.  Baseline and 2-year follow-up measurements will be acquired 
using spirometry, plethysmography, diffusing capacity of the lung for carbon monoxide (DLCO), St. George’s 
Respiratory Questionnaire (SGRQ), 6-minute walk test (6MWT), thoracic CT and hyperpolarized helium-3 
(3He) and xenon 129 (129Xe) MRI.  TINCan provides a unique opportunity to quantify and compare novel lung 
structure-function measurements and investigate their relationship with well-established clinical measurements 
and outcomes. Such intermediate endpoints of COPD may be used to stratify patients for personalized treatments 
and to develop new treatments to improve outcomes, a long-standing clinical goal.
Abbreviations: Thoracic Imaging Network of Canada, TINCan; computed tomography, CT; magnetic resonance imaging, MRI; Global 
initiative for chronic Obstructive Disease, GOLD; diffusing capacity of the lung for carbon monoxide, DLCO; St. George’s Respiratory 
Questionaire, SGRQ; 6-minute walk test, 6MWT; helium-3, 3He; xenon-129, 129Xe; COPD Genetic Epidemiology, COPDGene; Global 
Chest Symptoms Questionaire, GCSQ; Capacity of Daily Living questionnaire, CDLM; Food Frequency Questionaire, FFQ; Community 
Healthy Activities Model Program for Seniors, CHAMPS; Short Form-36 version 2, SF-36V2; Hospital Anxiety and Depression Scale, 
HADS; Short Form of the Health and Labour Questionaire, SF-HLQ; COPD Assessment Test, CAT; cardiopulmonary exercise test, CPET; 
Centre for Epidemiological Studies of Depression, CES-D; Functional Assessment of Chronic Illness Therapy, FACIT;  Canadian Chronic 
Obstructive Lung Disease study, CanCOLD; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints, ECLIPSE; 
Subpopulations and Intermediate Outcomes Measures in COPD, SPIROMICS; American Thoracic Society, ATS; European Respiratory 
Society, ERS; forced expiratory volume in 1 second, FEV1; functional residual capacity, FRC; residual volume, RV; total lung capacity, TLC; 
percent of predicted value, %pred; nitrogen gas, N2; lumen area, LA; airway wall area, Aaw; wall area percentages, WA%; internal perimeter 
of 10mm, Pi10; Hounsfield units, HU; relative area with attenuation values below -950, RA-950; low attenuation cluster, LAC; ventilation 
defect volume, VDV; ventilation defect percent, VDP; apparent diffusion coefficient, ADC; zero-inflated Poisson, ZIP
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Introduction
Chronic obstructive pulmonary disease (COPD) affects 
over 600 million people1 and is the third leading cause 
of death worldwide.2   Despite the huge societal, patient 
and health care system burden,3,4 COPD remains largely 
underdiagnosed5,6 and undertreated.7  Although COPD 
is currently diagnosed and its severity graded by non-
fully-reversible airflow limitation, there is tremendous 
heterogeneity in the underlying regional abnormalities 
within and across COPD severity categories.8 However, 
until recently, COPD patient measurements have been 
dominated by airflow and physiological measurements 
(e.g. inert gas washout tests9), or invasive histological 
measurements and this has limited the scope of research 
related to regional COPD phenotypes and their effect 
on outcomes and disease pathogenesis.
Unlike spirometry and other measurements made at 
the mouth, pulmonary imaging provides quantitative, 
regional and independent measurements of the 
underlying disease contributions in COPD.10,11 It is 
well-established that x-ray computed tomography (CT) 
provides a way to non-invasively measure the extent 
and regional distribution of emphysema and airway 
wall thickening in COPD10,12-14 CT measurements 
also correlate significantly with mortality,15 
disease progression,16-18 and exacerbation risk19 
and may identify suitable candidates for surgical 
intervention.20-23 Complementary to this, pulmonary 
functional imaging using hyperpolarized noble gas 
(3He and 129Xe) magnetic resonance imaging (MRI)24 
provides unique and simultaneous microstructure 
and functional information of both the airways 
and parenchyma.  MRI pulmonary structural and 
functional abnormalities are spatially reproducible over 
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time25-29 and correlate moderately with pulmonary 
function measurements.11,30-34  
Unfortunately, unlike the case for many chronic 
diseases where in vivo imaging has been exploited to 
improve patient outcomes, the inclusion of imaging in the 
clinical workup and prospective study of COPD therapies 
remains very limited.35, 36  Recently, however, large, 
prospective, multi-center cohort studies of COPD, such 
as the COPD  Genetic  Epidemiology (COPDGene)37 
the Canadian Chronic Obstructive Lung Disease 
(CanCOLD),38 the Evaluation of COPD Longitudinally 
to Identify Predictive Surrogate Endpoints (ECLIPSE)39 
and the Subpopulations and Intermediate Outcomes 
Measures in COPD (SPIROMICS)40 studies as shown in 
Table 1,  have included CT endpoints.  Although these 
multi-center studies have provided a wealth of clinical 
and biological data, there are no longitudinal COPD 
studies that have incorporated emerging and non-
radiation based imaging methods, such as provided by 
1H and hyperpolarized noble gas MRI.  Emerging MRI 
approaches may provide complementary functional 
and microstructural information related to COPD 
disease heterogeneity and progression.  Hence, the 
overarching objective of the Thoracic Imaging Network 
of Canada (TINCan) study is to determine quantitative 
structural and functional COPD imaging phenotypes 
that can be used to improve health outcomes in 
COPD patients.  The 4 key objectives of TINCan are: 
1) determine the significant cross-sectional univariate 
and multivariate relationships for 3He with 129Xe MRI 
and CT-derived phenotypes of airway and parenchymal 
abnormalities, 2) determine the longitudinal changes 
and relationships for 3He MRI-derived phenotypes 
of airway and parenchymal abnormalities with other 
COPD measurements, 3) determine the associations 
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Center and The Institute of Heart and Lung Health, St. Paul’s 
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between MRI and CT imaging phenotypes of COPD 
with exacerbations, and  4) determine whether MRI and 
CT phenotypes are predictors of longitudinal changes 
in pulmonary function measurements, lung volumes, 
symptoms and functional capacity.  To our knowledge, 
this is the first such large patient group comparison 
of structure-function imaging with prospective cross-
sectional and longitudinal components.  This study was 
designed to be complementary to larger ongoing COPD 
investigations and to address some of the important 
information gaps that remain.  Here we describe the 
study plan and aims for TINCan and the potential 
impact of this study to improve our understanding of 
COPD patient phenotypes.
Methods
Participants
As shown in the schedule of study assessments in Table 
2,  plans are to enroll 200 participants who will attend 
a baseline and a two-year follow-up visit.  Imaging 
evaluations include thoracic CT and hyperpolarized 
3He MRI at baseline and follow-up imaging at year two 
using both 3He and 129Xe MRI as well as CT.  Imaging 
will be performed at Robarts Research Institute 
(Ontario, Canada); MR image analysis will be performed 
at Robarts Research Institute and CT image analysis 
will be performed at Vancouver General Hospital 
(Vancouver, Canada).  The goal is to recruit 200 ex-
smokers with and without COPD between 50 and 80 
years of age, including approximately 100 ex-smokers 
without airflow limitation and COPD Global initiative 
for chronic Obstructive Lung Disease (GOLD) stage 
Unclassified (U) and 100 ex-smokers with COPD GOLD 
stages I, II, III and IV.  We previously demonstrated 
significant longitudinal changes in COPD ex-smokers 
in a two-year longitudinal pilot study and therefore, we 
limited our evaluation to ex-smokers.  Ex-smokers had 
ceased smoking ≥1-year prior to the study visit but 
there was no maximum cut-off for when ex-smokers 
had ceased smoking.  COPD was defined as post-
bronchodilator forced expiratory volume in 1 second 
(FEV1)/forced vital capacity (FVC) ratio less than 0.70 
according to the modified GOLD criteria.1
Recruitment and Retention
As shown in Figure 1,  thus far, 231 potential participants 
have been screened 
for participation in the 
TINCan study; of those 231 
individuals, 23 individuals 
cancelled prior to consent, 6 
individuals refused consent, 
16 individuals were excluded 
due to MRI incompatibilities 
and 4 individuals were 
excluded because they were 
unable to perform the 3He 
gas inhalation and breath-
hold.  Thus far, a total of 
182 participants have 
completed visit 1 and their 
demographic and pulmonary 
function measurements are 
provided in Table  3.  The 
projected recruitment phase 
for TINCan is 2 years.  An 
important goal of TINCan 
is to provide a better 
understanding of the early or 
mild subclinical disease, and 
therefore we plan to enroll a 
large number of ex-smokers 
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with normal pulmonary function.  Thus far, a total of 75 
ex-smokers without airflow limitation or GOLD U and 
107 individuals with COPD, including GOLD stage I 
(n=22), GOLD stage II (n=49), GOLD stage III (n=29) 
and GOLD stage IV (n=7), have been enrolled.  
Participant recruitment was primarily performed 
by local academic pulmonologists, advertisement in 
local newspapers, community newsletters and a local 
atherosclerosis prevention clinic.  All participants 
will provide written informed consent to the protocol 
that was approved by a local research ethics board 
and Health Canada and compliant with the Health 
Insurance Portability and Accountability Act.  Review 
and documented consent will be performed during 
the follow-up visit prior to participant evaluations. 
The primary responsibility of a full-time research 
coordinator (certified by the Association of Clinical 
Research Professionals) included management of 
recruitment and scheduling as well as participant 
retention activities.  Based on our previous experience 
with a pilot two-year longitudinal study where the 
retention rate was 90%,41 we expect similar participant 
retention over the two-year follow-up period. 
Pulmonary Function and Other Measurements
All participants will undergo, at baseline and at the 
two-year follow-up, post-bronchodilator spirometry 
and plethysmography, the St George’s Respiratory 
Questionnaire (SGRQ), used with permission,42 
and a 6-minute walk test (6MWT)43,44 to measure 
the 6-minute walk distance (6MWD).  Spirometry, 
plethysmography and diffusing capacity of the lung for 
For TINCan, 231 individuals were contacted and 208 individuals 
attended the baseline study visit.  Of the 208 individuals who 
attended the baseline visit, 6 individuals refused consent, 16 
individuals were excluded due to MRI incompatibilities and 4 
individuals were excluded because they were unable to perform the 
3He gas inhalation and breath-hold.  Complete visits, defined as one 
in which individuals were able to complete all study evaluations 
was performed for 182 individuals; 75 individuals did not have 
airflow limitation (FEV1/FVC≥0.70) and 107 individuals had 
COPD defined using spirometry according to GOLD criteria.1
carbon monoxide (DLCO) will be measured 
using body plethysmography (MedGraphics 
Corporation, Minnesota, USA) with the 
attached Medgraphics gas analyzer 
according to American Thoracic Society 
(ATS)/European Respiratory Society 
(ERS) guidelines.45-48  For all participants 
who complete the baseline study visit, 
the number of acute exacerbations 
requiring hospitalization or COPD-related 
hospitalizations will be reported using 
patient hospital records obtained with 
Cerner’s PowerChart® (Cerner Corporation, 
Missouri, USA) up to 5 years prior to the 
initial participant baseline visit as well as 
during the follow-up period.  
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CT Imaging
Thoracic CT will be acquired using a 64-slice (General 
Electric Health Care Milwaukee) CT system.  Baseline 
CT images will be acquired with patients at inspiration 
breath-hold after inhalation of  1.0L medical grade 
nitrogen (N2) from a 1.0 L Tedlar® bag (Jensen Inert 
Products, New Jersey, USA) from functional residual 
capacity (FRC) using the same imaging protocol as the 
ECLIPSE study39 and the same lung volume used with 
an MRI.  We use a Tedlar® bag filled with N2 instead of 
room air for CT imaging because the hyperpolarized 
3He gas depolarizes when exposed to oxygen (O2) and 
therefore, the gas dispensing apparatus must remain 
completely free of O2 in order to avoid the potential for 
cross-contamination.  The baseline CT is acquired at the 
same lung volume as used with an MRI to enable image 
co-registration; CT-MRI co-registration will allow us 
to investigate the relationship between morphological 
CT airway measurements and hyperpolarized noble 
gas MRI static ventilation measurements.  In order 
to evaluate regional pulmonary gas trapping, as 
well as to differentiate regions of gas trapping due 
to emphysematous tissue destruction from small 
airway disease using inspiratory to expiratory image 
registration,49 a full inspiration and full expiration 
CT will be performed at the two-year follow-up using 
the same imaging protocol as the COPDGene37 and 
CanCOLD38 studies.  Importantly, the CT images 
acquired at the two-year longitudinal follow-up will 
not be used to evaluate longitudinal measurement 
changes.  Both baseline and longitudinal CT will be 
used for investigating relationships between MRI and 
CT measurements. 
     All CT images will be quantified using the Pulmonary 
Workstation 2.0 (VIDA Diagnostics, Inc., Iowa, USA). 
CT structural airway measurements will include: 1) 
lumen area (LA), 2) airway wall area (AAW) and 3) wall 
area percentage (WA%) measured for the segmental and 
subsegmental airways,10 and, 4) the square root of airway 
wall thickness for airways with an internal perimeter of 
10mm (Pi10).50  CT structural emphysema measurements 
will include:  1) the relative area with attenuation values 
below −950 Hounsfield units [HU] (RA950),13 and, 2) 
the low attenuation cluster (LAC) analysis of connected 
regions with CT densitometry values < -950 HU.51-53 
At the two-year follow-up, inspiratory and expiratory 
CT images will be co-registered to regionally identify 
normal lung, emphysema and air trapping as recently 
described.49
MR Imaging
Hyperpolarized 3He MRI will be acquired using a 3.0 
Tesla MR750 system (General Electric Health Care, 
Milwaukee, WI USA).  Participants will undergo breath-
hold imaging for acquisition of conventional 1H MRI, 
3He static ventilation MRI and 3He diffusion-weighted 
MRI.  Conventional 1H MRI will be acquired during 1.0L 
breath-hold of N2 from a 1.0 L Tedlar® bag from FRC. 
3He static ventilation and diffusion weighted imaging 
will be performed following inhalation of a 3He/N2 gas 
mixture (3He dose = 5 ml/kg body weight) from a 1.0 
L Tedlar® bag from FRC as previously described.25  At 
visit 2, a hyperpolarized 129Xe MRI will also be acquired 
on the same system as 3He MRI using 129Xe gas doses 
(50/50 129Xe/4He) administered in 1.0L Tedlar® 
bags with 129Xe MRI static ventilation and diffusion-
weighted images acquired, as previously described.34 
There was not a commercially-available 129Xe polarizer 
that was approved for human participants during 
baseline enrollment, and therefore, hyperpolarized 
129Xe was not performed at visit 1 for all participants. 
However, a small proof of concept study was performed 
in 10 TINCan COPD participants at visit 1 as previously 
described.34
     All MR images will be evaluated using custom-built 
software generated using MATLAB R2007b (The Math-
works Inc., Massachusetts, USA).  For 3He and 129Xe 
MRI static ventilation images, regions of signal void or 
ventilation defects will be quantified as the ratio of the 
ventilation defect volume (VDV) to the thoracic cavity 
volume (segmented from 1H MRI) to generate the whole 
lung ventilation defect percentage (VDP)11,54;  3He 
and 129Xe apparent diffusion coefficient (ADC) maps 
will also be generated from diffusion-weighted images 
using custom built software (MATLAB R2007b) .55  
     Figure 2  shows for 2 representative asymptomatic 
ex-smokers with normal pulmonary function and 2 
representative COPD participants at baseline, the CT 
density mask highlighting areas with CT densitometry 
values less than -950 HU, CT low attenuation clusters 
registered to the 3D reconstruction of the CT airway tree 
for measurement of airway dimensions.  The 1H and 3He 
MRI co-registered central coronal slices (3He shown in 
blue) are also shown to highlight 3He MRI ventilation 
defects, and the 3He MRI ADC maps are provided 
as evidence of both ventilation and morphological 
abnormalities in these individuals.
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Data and Statistical Analysis Plan 
There are 4 key objectives for the TINCan study and 
these are enabled by the statistical analysis plan. 
First, we will determine the significant cross-sectional 
univariate and multivariate relationships for 3He with 
129Xe MRI and CT-derived phenotypes of airway 
and parenchymal abnormalities.  Pearson correlation 
coefficients and linear regression will be performed to 
determine the univariate relationships for baseline 3He 
For 4 representative participants (2 asymptomatic ex-smokers without COPD and 2 COPD 
ex-smokers) the CT density mask highlighting areas with CT densitometry values below 
-950 HU, CT LAC of connected regions of the lung with CT densitometry values below 
-950 HU registered to the 3D reconstruction of the airway tree for measurement of airway 
dimensions, 1H and 3He MRI registration (3He shown in blue) and 3He ADC maps are shown. 
Imaging evidence of disease is apparent in some asymptomatic ex-smokers without COPD, 
as shown for Participant 2 (72 year-old male, FEV1=122%pred, FEV1/FVC=80%, DLCO=73%pred, 
RA950=4%, VDP=17%, ADC=0.25cm2/s) but not Participant 1 (70 year-old male, 
FEV1=101%pred, FEV1/FVC=75%, DLCO=113%pred, RA950=1%, VDP=4%, ADC=0.26cm2/s).
For the COPD ex-smokers, significantly greater emphysema extent is demonstrated by 
the highlighted areas on the CT density mask and bright ADC maps in Participant 4 (76 
year-old female, FEV1=79%pred, FEV1/FVC=64%, DLCO=63%pred, RA950=33%, VDP=36%, 
ADC=0.63cm2/s), while a lesser extent is observed for Participant 3 (76 year-old female, 
FEV1=52%pred, FEV1/FVC=42%, DLCO=18%pred, RA950=1%, VDP=17%, ADC=0.31cm2/s).
and 129Xe gas distribution measurements 
(regional and whole lung VDV, VDP) with CT 
airway disease measurements and all other 
participant measurements.  Multivariate 
linear regression models will also be 
constructed for predicting SGRQ total score 
and 6MWD using CT (Pi10, RA950) and 3He 
MRI (VDP, ADC) phenotype measurements, 
adjusted for sex, BMI, FEV1, and DLCO.
Second, we will determine the longitudinal 
changes and relationships for 3He 
MRI-derived phenotypes of airway and 
parenchymal abnormalities with other 
COPD measurements (SGRQ, 6MWD, 
spirometry, plethysmography and DLCO).  We 
will determine the significant longitudinal 
changes for 3He MRI measurements 
using paired two-tailed t-tests.  Pearson 
correlation coefficients and linear regression 
analyses will be performed to determine the 
relationships between the change in 3He MRI 
measurements with the longitudinal change 
in physiological measures (FEV1, FEV1/
FVC, RV, DLCO), functional capacity (6MWD) 
and quality of life (SGRQ) measurements. 
We previously performed and reported the 
results of a pilot longitudinal study in 15 
ex-smokers with COPD that demonstrated 
statistically significant 3He ADC and VDP 
worsening in 2 years.41 Based on this pilot 
study, with 100 COPD participants enrolled 
thus far and a longitudinal retention rate of 
90% expected, this study has sufficient power 
to detect significant longitudinal changes for 
3He MRI measurements (α=.05, ß=0.20 and 
power=.80).  
Third, the associations between imaging 
phenotypes of COPD with exacerbations 
will be evaluated.  To accomplish this, a zero-
inflated Poisson (ZIP) model will be used to 
determine the relationship between selected variables 
with COPD exacerbations, including hospitalization 
and death.  The variables that will be included in the 
regression include:  age, sex, BMI, smoking status, FEV1, 
DLCO, RV, SGRQ, 6MWD, CT RA950, CT WA%, 3He MRI 
VDP, and 3He MRI ADC.  We have recently evaluated the 
association between imaging phenotypes of COPD with 
the number of hospitalizations and demonstrated that 
over a 5-year period, 58 hospitalizations occurred.56  We 
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also reported that 3He VDP was a significant predictor 
of hospitalization due to COPD exacerbation.56 
Therefore, based on this study we are powered to detect 
statistically significant associations between 3He MRI 
measurements with all COPD acute exacerbations, 
including those that resulted in treatment, emergency 
department visits and hospitalizations, as well as 
COPD-related mortality.
Finally, we will determine whether MRI and CT 
phenotypes are predictors of longitudinal changes 
in pulmonary function measurements, lung volumes, 
symptoms and functional capacity. Using mixed 
linear regression analyses adjusted for cofounders, 
we will determine which baseline imaging phenotype 
measurements have the strongest relationship with 
the longitudinal changes in health status (SGRQ), 
functional capacity (6MWD) and FEV1.  Cofounders 
will include age, sex, smoking status, BMI, and baseline 
FEV1.  In a similar manner we will also use hierarchical 
clustering models (Principal Component analysis) 
and generate icicle plots (showing cases as rows and 
number of clusters as columns) and dendograms (or 
hierarchical tree diagrams).  Principal component 
analysis using hierarchical clustering is appropriate 
for smaller samples (typically < 250) and we will 
generate a dataset for all evaluable participants with 
3He and 129Xe MRI structural and functional variables 
as well as CT-derived variables.  In this way, we can 
attempt to determine which clusters of imaging and 
other measurements are the predictors of longitudinal 
progression and outcomes. 
Discussion
In COPD, the current gold standard approach for 
evaluating disease severity, disease progression 
and treatment response relies on lung function 
measurements that provide little information about the 
underlying morphological, anatomical and functional 
abnormalities that result in symptoms, airflow limitation 
and adverse outcomes.  To address this critical gap in 
knowledge, TINCan was developed and implemented. 
The major anticipated value of TINCan is an enhanced 
understanding of COPD-imaging phenotypes, and 
their relationship to well-established measurements of 
COPD and subclinical disease and disease progression. 
In addition, we hypothesize that non-invasive COPD-
imaging phenotypes directly reflect the underlying 
abnormalities in COPD and these can be used as 
intermediate endpoints in the development of new 
treatment approaches. 
      One important technical goal for TINCan is to provide 
tools and methods that streamline image analysis 
workflow to accelerate the translational potential of 
pulmonary functional MRIs.  Therefore, we focused 
on developing image segmentation and registration 
tools to quantify measurements with high precision for 
detecting small measurement changes in treatment or 
longitudinal studies.  Towards this goal, we developed 
a multi-step, semi-automated 3He-1H registration 
and segmentation method57 and demonstrated that 
it provides excellent inter-/intra-observer precision 
and good agreement with expert observers’ manual 
measurements.  With the development of image 
analysis tools underway, we can apply these tools to the 
TINCan cohort and be confident that the longitudinal 
changes measured are likely due to disease changes. 
Another important goal of TINCan is to provide a better 
understanding of the early or mild subclinical disease 
observed in ex-smokers with normal spirometry.  We 
recently demonstrated that abnormal DLCO in ex-
smokers without COPD was related to worse health 
status, functional capacity and elevated 3He ADC 
consistent with early emphysema revealed by 3He MRI 
but not CT.58 At the 2-year follow-up, we will determine 
whether such smokers with 3He MRI evidence of early 
or mild emphysema (but without airflow limitation) 
show evidence of progressive disease.    
      For a small group of participants we have incorporated 
hyperpolarized 129Xe MRI as part of the baseline visit 
to test hypotheses related to potential differences in 
129Xe and 3He MRI ventilation.  To better understand 
any potential differences between 3He and 129Xe MRI 
gas distribution, we quantitatively compared 3He and 
129Xe MRI in COPD participants and observed that 
129Xe VDP was significantly greater than 3He VDP.34 
We also observed that the regions of decreased 129Xe 
ventilation were spatially and significantly correlated 
with regions of emphysema.33 Taken together, these 
important findings suggest that 129Xe gas may be more 
sensitive to changes in both the airways and parenchyma 
in COPD, and therefore may be more sensitive than  3He 
for detecting changes at the 2-year follow-up.
The important next step of the TINCan cohort 
is to complete enrollment and then follow-up with 
all participants in order to evaluate longitudinal 
changes.  We will identify whether MRI phenotypes 
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detect significant disease progression, how changes 
in MR imaging-derived measures relate to changes in 
physiologic and health outcome measurements, and 
determine which baseline imaging phenotypes can 
predict declines in quality of life, functional capacity 
and physiologic measurements.  We will also determine 
whether imaging phenotypes can independently 
identify individuals with more frequent exacerbations 
and more rapid declines in lung function.
In contrast to other cohort studies of COPD,37-40 
TINCan’s novelty stems from its incorporation of 
emerging non-radiation-based imaging measurements 
in addition to conventional CT.  These emerging imaging 
methods have the potential to provide complementary 
quantitative information regarding subclinical and 
clinical COPD pathophysiologies that may eventually 
allow for more personalized treatment.  Another 
strength of TINCan is the inclusion of individuals often 
excluded from COPD cohort studies.  For example, 
TINCan includes a relatively large group of ex-smokers 
without COPD.  Identifying imaging phenotypes 
that can characterize these unique pathologies non-
invasively and evaluate their relationships with disease 
progression and exacerbations is an important goal for 
the TINCan study.
In conclusion, here we describe the largest prospective, 
longitudinal pulmonary structure-function imaging 
study of COPD planned to-date using emerging 
MRI and CT imaging methods.  Upon completion we 
will have a better understanding of the relationships 
between imaging phenotypes with well-established 
lung function and health status measurements, as well 
as outcomes, in a well-defined and relatively large group 
of ex-smokers.  Finally, once complete, the resulting 
validated imaging measurements may be considered 
as intermediate endpoints for future COPD treatment 
studies to better target therapy, a long-standing research 
and clinical goal for COPD. 
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